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Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emergent coronavi-
rus that has caused a worldwide pandemic. Although human disease is often asymptomatic,
some develop severe illnesses such as pneumonia, respiratory failure, and death. There is
an urgent need for a vaccine to prevent its rapid spread as asymptomatic infections account-
ing for up to 40% of transmission events. Here we further evaluated an inactivated rabies
vectored SARS-CoV-2 S1 vaccine CORAVAX in a Syrian hamster model. CORAVAX adju-
vanted with MPLA-AddaVax, a TRL4 agonist, induced high levels of neutralizing antibodies
and generated a strong Th1-biased immune response. Vaccinated hamsters were protected
from weight loss and viral replication in the lungs and nasal turbinates three days after chal-
lenge with SARS-CoV-2. CORAVAX also prevented lung disease, as indicated by the signif-
icant reduction in lung pathology. This study highlights CORAVAX as a safe, immunogenic,
and efficacious vaccine that warrants further assessment in human trials.
Author summary
We have developed an inactivated rabies virus vectored vaccine platform that has been
used to develop a vaccine against SARS-CoV-2 (CORAVAX). CORAVAX induced high
levels of neutralizing antibodies against SARS-CoV-2. Here we show that vaccinated ham-
sters, the best animal model for COVID-19, were protected against viral replication, indi-
cating that this vaccine can stop transmission. CORAVAX also prevented lung disease.
Rabies virus vaccines have been used in more than 100 million people worldwide, are safe
and used in children and pregnant women. Therefore, it is anticipated that CORAVAX
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will generate robust immune responses against SARS-CoV-2 in humans that may also
mimic the long-term protection seen in rabies vaccines.
Introduction
More than 150 vaccines against SARS-CoV-2 are in preclinical trials, and over 51 candidate
vaccines are in human trials [1]. They include adenovirus and other viral vector-based vac-
cines and protein-, DNA-, and mRNA-based vaccines [2]. These vaccine approaches have dif-
ferent advantages and disadvantages. mRNA vaccines, including the 2 U.S. FDA-approved
coronavirus vaccines from Moderna and Pfizer-BioNTech, can be produced efficiently, but
they can be costly to produce and have temperature sensitivity [3]; furthermore, questions
remain unanswered about the longevity of the immune response with mRNA vaccines and if
they block transmission. Meanwhile, DNA-based vaccines benefit from temperature stability
and low production costs, but their immunogenicity has been a concern, and the need for
multiple vaccinations challenges their feasibility [4]. Virus-like particle (VLP)- and recombi-
nant protein-based vaccines have an excellent safety advantage because they do not replicate
in the host, and often they can also be made more temperature stable. However, VLP-based
vaccines are not always as immunogenic as replication-competent or replication-deficient
viral vector vaccines and often require an adjuvant to increase their immunogenicity to an
adequately protective level [5,6]. Finally, viral vector-based vaccines the advantage of being
typically cheaper to produce, efficacious after a single vaccination, and often highly immuno-
genic [1,7–9], but those based on live viral vaccines sometimes fail because of safety concerns
and production scalability, and they usually require a low storage temperature [8]. The disad-
vantages of viral vector vaccines are largely overcome, however, when they are based on an
inactivated virus.
Using this approach, we have developed an inactivated viral vector vaccine against
SARS-CoV-2 that is based on the rabies virus (RABV). We have previously utilized this
approach to develop inactivated RABV-based vaccines for several other human pathogens
(e.g., Ebola virus, Marburg virus, Lassa Fever virus and others) [10–27]. These rabies virus-
based vaccines have been proven to be highly immunogenic and protective against several
emerging viral infections and bacterial toxins, as well as safe and temperature stable [28]. The
RABV vaccine itself has been safely used for decades in more than 100 million people, includ-
ing children, pregnant women, and the elderly, and proven to result in long-lasting immunity
[29].
CORAVAX, our rabies vectored SARS COV-2 vaccine, expresses the S1 domain of the
SARS-CoV-2 spike (S) protein fused to part of the N terminal domain of the RABV glycopro-
tein (G) and is incorporated in RABV particles. Mice immunized with adjuvanted CORA-
VAX developed potent neutralizing antibodies about 5–10 times higher than the virus-
neutralizing antibodies (VNA) detected in convalescent sera from SARS-CoV-2 infected peo-
ple [30]. Here, to learn more, we evaluated the efficacy of CORAVAX in the Syrian hamster
model for SARS-CoV-2, which is currently considered the best model to study COVID-19
therapies and therapeutics. Our results showed that two immunizations with the adjuvanted
CORAVAX vaccine induced high VNA and cleared infectious SARS-CoV-2 from the lung
and the nasal turbinates on day 3 post challenge. Moreover, the pathology induced by SARS--
CoV-2 was reduced with only some early infiltration of cells into the lung tissue. Taken
together, this study indicates that CORAVAX warrants further development as a disease-pre-
venting human vaccine.
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Results
Immunogenicity of CORAVAX in Syrian hamsters
CORAVAX a rabies vectored SARS COV-2 vaccine was generated by inserting the S1 subunit
of the SARS-CoV-2 Spike into the SAD-B19 rabies vaccine strain. To promote the incorpo-
ration of the S1 domain, we prepared a fusion protein between SARS-CoV-2 S1 and RABV G.
Toward this approach, the N-terminal 682 aa of SARS-CoV-2 S1 were fused to a truncated
RABV glycoprotein, which comprises 31 aa of the ectodomain (ED) of RABV G and the com-
plete cytoplasmic domain (CD) and transmembrane domain of RABV G to allow chimeric gly-
coprotein incorporation into RABV virions. We previously showed that CORAVAX induces
high virus neutralizing antibodies as a live or inactivated vaccine in mice [30]. Here we extend
these studies in the more relevant SARS CoV-2 Syrian Hamster model of severe disease.
To evaluate the immunogenicity and efficacy of the CORAVAX vaccine in golden Syrian
hamsters, we vaccinated each group comprising 12 animals with either 10 μg of inactivated
CORAVAX or control vaccine FILORAB1 (rabies vectored Ebola vaccine) adjuvanted with
MPLA-AddaVax in a 100 μL injection volume via the intramuscular route (Fig 1A). The ani-
mals received a prime on day 0 and a booster on day 28. Blood was collected on days -2, 26,
and 56 (Fig 1B). On day 60, vaccinated and control hamsters were challenged intranasally with
a dose of 105 PFU of the SARS-CoV-2 isolate USA_WA1/2020 [31].
In the next step, sera from immunized hamsters and controls were assayed for SARS CoV-2
specific antibody responses by ELISA specific for SARS-CoV-2 S1 and receptor binding site
(RBD) (Fig 2). High titers of SARS-COV-2 S1 specific IgG responses were detected in the
CORAVAX vaccinated hamsters on day 26 with no significant differences in antibody titers
on day 56 (Fig 2A). As expected, no SARS-CoV-2 S1 immune response was detected in the
control animals vaccinated with the EBOV vaccine FILORAB1. As previously seen for other
inactivated and adjuvanted RABV-based vaccines, CORAVAX induced a Th1 biased immune
response as indicated by the high SARS CoV-2 S1 IgG2/3 responses detected on days 26 and
56 (Fig 2B). We could not detect S1 specific IgG1 responses in any of the hamsters. Similar to
the responses detected by ELISA to SARS CoV-2 S1, we observed high titers of SARS-CoV-2
VNA with mean titers of 976 ± SD 685 on day 56 (Fig 2C). Of note, no VNA against SARS--
CoV-2 were detected in FILORAB1 immunized animals before the challenge (Fig 2C).
We next analyzed the immune responses post-challenge (p.c.). By day 63, 3 days p.c., we
observed a significant reduction (P = 0.0069) in S1 IgG responses in CORAVAX vaccinated
animals, while no S1-specific IgG responses were observed in the controls hamsters
(FILORAB1) (Fig 2A–2C). By day 75, both in CORAVAX and FILORAB1 vaccinated and
challenged hamsters, S1-specific IgG and VNA were detected (Fig 2A, 2B and 2C). However,
both S1-specific IgG and VNA were significantly higher in the CORAVAX vaccinated animals
on day 75 (Fig 2A–2C). Moreover, p.c. CORAVAX vaccinated animals indicated a more
robust Th1-biased immune response compared to FILORAB1 control animals, as indicated by
the IgG2/3 responses (Fig 2B). In addition to the antibodies directed against the receptor-bind-
ing domain (RBD) SARS-CoV-2, high RBD-specific IgG titers were detected in the CORA-
VAX vaccinated animals on day 56 as well as p.c. on days 63 and 75. Interestingly, the RBD
IgG titers were undetectable in the FILORAB1 vaccinated controls on day 63 but were higher
than the ELISA titers detected in CORAVAX vaccinated animals on day 75, challenging the
dogma that high ELISA titer against RBD predict the VNA against SARS-CoV-2 (Fig 2D).
CORAVAX induces potent immune responses against RABV
We also analyzed the VNA induced by the two vaccines against RABV. CORAVAX is a vac-
cine against both SARS-CoV-2 and RABV, and in large part of the world RABV is still a
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significant problem, annually killing about 55,000 people, mostly children. We detected a titer
of anti-RABV neutralizing antibodies above the WHO’s 0.5 IU standard in both the
FILORAB1 and CORAVAX vaccinated animals, with no significant differences (Fig 3).
CORAVAX protects the hamsters from weight loss and viral burden in the
lungs and nasal turbinates post-SARS CoV-2 challenge
The hamsters were challenged intranasally on day 60 with 105 PFU of SARS-CoV-2 isolate
USA_WA1/2020 and were monitored for up to 15 days. The CORAVAX vaccinated animals
showed significantly less weight loss than the FILORAB1 controls (P = 0.0098), which lost
more than 10% weight and recovered only at day 11 (Fig 4). At days 3 and 15 p.c., half of the
hamsters in each study group were euthanized, and lungs and nasal turbinates were harvested,
and virus isolated to determine viral loads by plaque reduction assay (Fig 5A and 5B). Addi-
tionally, the number of viral copies was analyzed by RT-qPCR assay (Fig 5C and 5D). The lack
Fig 1. Vaccine constructs and vaccination schedule. A) Schematic illustration of CORAVAX, the rabies virus-based SARS-CoV-2
vaccine construct wherein a SARS-CoV-2 S1 RABV G chimeric protein cDNA was inserted between the N and P genes of the
SAD-B19-derived RABV virus vaccine vector BNSP333 and control vaccine FILORAB1, the rabies virus-based EBOLA vaccine used in
this study. B) Syrian hamsters were immunized on day 0 and day 28 with 10 μg chemically inactivated CORAVAX or FILORAB1 with
MPLA-AddaVax adjuvant. The animals were challenged on day 60 with a dose of 105 PFU of the SARS-CoV-2 isolate USA_WA1/2020.
Serum was collected from each hamster at days -2, 26, 56, 63, and 75 for analysis. Animals were necropsied at days 63 (day 3 p.c.) and 75
(day 15 p.c.).
https://doi.org/10.1371/journal.ppat.1009383.g001
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of weight loss coincided with the absence of any infectious virus in the lungs and nasal turbi-
nates of the CORAVAX vaccinated animals on days 3 and 15 p.c. (Fig 5A and 5B).
In contrast to the CORAVAX immunized animals, the FILORAB1 controls had high titers
of infectious virus in the lungs and nasal turbinates on day 3 p.c.. As expected, both groups
cleared the SARS-CoV-2 15 days.
A similar trend between the two groups was detected when RNA copies of SARS-CoV-2
were analyzed via RT-PCR. CORAVAX vaccinated animals had significantly reduced RNA
copies in the lungs and nasal turbinates at necropsy (day 3 and 15 p.c.) than the control
FILORAB1 group (Fig 5C and 5D). The presence of viral RNA in the absence of infectious
SARS-CoV-2 is well-established and based on the stability of the genome of SARS-CoV-2
[32,33]. However, it should be noted that the ~1000-fold lower copy number in CORAVAX
vaccinated animals indicates a significant reduction of viral replication by CORAVAX.
CORAVAX vaccinated animals have significantly reduced lung pathology
than controls
Lung sections were collected from control and vaccinated animals at days 3 and 15 p.c. (Figs 6
and 7). Sections were scored in a blinded manner. Histopathological changes consistent with
viral interstitial pneumonia were noted in all animals, regardless of treatment or time of collec-
tion (Fig 6, representative pathology pictures; Fig 7A and 7B mean overall pathology scores).
These included consolidation, widespread alveolar septal thickening, and airway pathology
consisting of airway epithelial hyperplasia and accumulation of inflammatory cells in airways,
occasionally leading to obstruction of the lumen. On day 3 p.c., CORAVAX vaccinated ani-
mals had significantly lower average pathology scores. Specifically, component scores for
inflammatory foci size and number and airway pathology were improved (Fig 7A). Animals
cleared the virus by day 15 (Fig 5A and 5B), and consistent with expected tissue damage repair
following clearance, we observed reduced pathology in both CORAVAX and the control
FILORAB1 vaccinated animals (Fig 7B).
Fig 2. SARS CoV-2 immune responses. Serum samples collected from each hamster were evaluated for SARS-CoV-2
S-specific immune responses by A) ELISA, Anti-SARS CoV-2 S1 IgG responses represented as EC50 titers over time,
B) ELISA, Anti-SARS CoV-2 IgG2/3 responses, C) Virus neutralizing antibodies, and D) ELISA, Anti-SARS COV- 2 S
RBD IgG responses. The CORAVAX vaccine group is shown in blue and the FILORAB1 group in black. For A-D,
mean titers ± SD are depicted for each group per time point. P values determined by Mann-Whitney test. Only
significant differences are depicted.
https://doi.org/10.1371/journal.ppat.1009383.g002
Fig 3. Rabies virus neutralizing antibodies Hamster day 56 sera were assessed for RABV VNA. Dotted line
represent 0.5 I.U/mL. Only significant differences are depicted.
https://doi.org/10.1371/journal.ppat.1009383.g003
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Discussion
There is an urgent need for a safe and effective vaccine against SARS-COV-2 that can be
administered to pregnant women, children, elderly and the immunocompromised. The two
FDA emergency use authorization (EUA) COVID-19 vaccines, BNT162b2 (Pfizer-BioNTech)
and mRNA-1273 (Moderna), are based on the mRNA platform have shown promising results
with efficacy above 90% [34,35]. Neither of these EUA COVID-19 vaccines are approved for
use in pregnant women, breastfeeding mothers, children below the age of 18, and the immu-
nocompromised [36], and they have yet to demonstrate long-lasting immune responses.
Therefore, other vaccine approaches are still needed.
This study is the first to show the efficacy of a RABV vectored COVID-19 vaccine, CORA-
VAX, in the Syrian hamster model of severe disease. The rabies vaccine vector has several
advantages: 1) it has an excellent safety profile, as it is used as an inactivated vaccine; 2) there is
historical evidence of long-term immunity; 3) it can be administered safely and effectively to
the vulnerable populations of children, pregnant women, elderly, and immunocompromised;
4) pre-existing rabies immunity does not affect the boosting potential of the vaccine; 5) RABV
virions incorporate foreign antigens easily; and 6) RABV-based vaccines show excellent tem-
perature stability [2,19,28].
Our vaccine approaches used only part of the SARS-CoV-2 spike protein. Using S1 rather
than the full spike protein as the immunogen ensures the immune responses against the
important neutralizing epitopes identified in human convalescent patients recognizing the
RBD, NTD S1, and quaternary epitope that bridges the two RBDs [37]. Our use of the S1 in
CORAVAX might explain the higher VNA titers in the Syrian hamsters compared to other
COVID-19 vaccines utilizing the full spike as the antigen in yellow fever and Ad26 vectors as
well as in a DNA vaccine platform [38–40].
Several candidate vaccines against COVID-19 utilizing DNA, RNA, viral vectors, inacti-
vated vaccines and subunit vaccine platforms are in various stages of pre-clinical or clinical
development [41]. While the immune correlates of protection are yet to be determined, most
Fig 4. Hamster body weight after SARS CoV-2 infection. Hamsters were vaccinated at day 0 and day 28, challenged
intranasally with 105 PFU SARS-CoV-2 at day 60. Percent change in body weight. CORAVAX vaccine group is shown
in blue and FILORAB1 group in black. N = 12 for FILORAB1 group (6 hamsters euthanized at day 3 p.c.) and N = 11
for CORAVAX group (6 hamsters euthanized at day 3 p.c.). Body weight P value determined by Wilcoxon test.
P> 0.123 (ns), P< 0.033 (�), P< 0.002 (��), P< 0.001 (���).
https://doi.org/10.1371/journal.ppat.1009383.g004
PLOS PATHOGENS Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1009383 March 25, 2021 7 / 19
candidate vaccines trials compare their antibody and neutralizing response to SARS-CoV-2
convalescent sera. Clinical trials with convalescent plasma treatment have shown little or no
significant difference in outcomes among SARS-CoV-2 patients compared to placebo group
[42,43]. Also, most convalescent plasma samples obtained from individuals who recover from
COVID-19 do not contain high levels of neutralizing activity [44].
CORAVAX induced high SARS CoV-2 S1 and RBD specific antibody and neutralizing
titers on day 26 post the prime vaccination. The antibody and neutralizing titers were slightly
(but not significantly) increased on day 56 after the boost (on day 28). CORAVAX also
induced a strong Th1 biased immune response indicated by the IgG2/3 response before the
challenge. Post-challenge, CORAVAX vaccinated animals induced significantly higher S1 IgG
titers than the controls that correlated well with the neutralizing antibody response. Interest-
ingly the RBD IgG titers were higher in the control animals at day 15 p.c. than CORAVAX
Fig 5. SARS-CoV-2 tissue viral load in hamsters. Hamsters were challenged intranasally with 105 PFU SARS-CoV-2, and half of the animals in
each group were euthanized at days 3 and 15 p.c. Right lungs (A, C) and nasal turbinates (B, D) from each animal were homogenized in media and
viral loads were determined by plaque assays on Vero E6 cells (A, B) or by qRT-PCR (C, D). The limit of detection for the plaque assay was 70
PFU per lung and 35 PFU per nasal turbinate. The limit of detection for the qRT-PCR assay is 10 copies. The CORAVAX vaccine group is shown
in blue and the FILORAB1 group in black. Data represent mean ± S.D., N = 6 for FILORAB1 group day 3 and day 15 time points, and N = 6 for
CORAVAX group day 3 and N = 5 for CORAVAX group day 15 time points. P values determined by Mann-Whitney test. Only significant
differences are depicted.
https://doi.org/10.1371/journal.ppat.1009383.g005
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Fig 6. SARS-CoV 2 lung pathology. Representative histological images of SARS-CoV-2 infection in control and vaccinated hamster lungs. A
and B, low magnification images, day 3 p.c. lungs. A: FILORAB1 control, B: CORAVAX vaccinated. C and D, high magnification of A and B
detailing specific pathological features, location indicated by asterisks on low magnification images. Infiltration of parenchyma and airways by
mononuclear inflammatory cells is prominent in control animal. Notable improvement in airway infiltration observed in vaccinated animals.
Varying degrees of consolidation and septal thickening are present in control and vaccinated animals. E and F, low magnification images, day
15 p.c. lungs. E: FILORAB1 control, F: CORAVAX vaccinated. G and H, high magnification of E and F detailing specific pathological features,
PLOS PATHOGENS Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model
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location indicated by asterisks (�) on low magnification images. Significant airway infiltration is absent in all animals, but other aspects of
inflammatory pathology persist, such as epithelial hyperplasia Overall consolidation improved in vaccinated animals but did not reach
statistical significance.
https://doi.org/10.1371/journal.ppat.1009383.g006
Fig 7. Comparative pathology scores for lungs from CORAVAX vaccinated and control hamsters post SARS-CoV-2 challenge. Scores at 3 days (A) and
15 days (B) p.c. Scores are displayed for overall lung pathology and individual criteria, including consolidation or extent of inflammation, type inflammatory
foci, airway pathology, and septal thickening. The pathology scores (mean) were calculated based on the criteria described in S1 Table. The CORAVAX
vaccine group is shown in blue and the control group in black. Data represent mean ± S.D., N = 6 for FILORAB1 group day 3 and day 15 time points and
N = 6 for CORAVAX vaccine group at day 3 and N = 5 for CORAVAX day 15 time points. P> 0.123 (ns), P< 0.033 (�), P< 0.002 (��), P< 0.001 (���). Only
significant differences are depicted.
https://doi.org/10.1371/journal.ppat.1009383.g007
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vaccinating animals. The correlation of the S1 IgG titers with that of neutralizing antibody
responses in the CORAVAX vaccinated animals suggests that the S1 IgG titers are a better pre-
dictor of protection than the RBD IgG titers. Our result aligns with the Chi et al. study that
identified non-RBD binding, SARS CoV-2 S1 N terminal domain (NTD) binding neutralizing
antibodies isolated from convalescent patients [45]. It has also been suggested that the non-
RBD binding S1 antibodies could be restraining the conformational changes of the S protein,
thereby preventing viral entry. Conversely, vaccines that induce only RBD antibodies alone
might induce resistance mutations in the virus [46]. CORAVAX induces antibodies against
the RBD as well other epitopes of S1. Antibodies induced in the CORAVAX vaccinated ham-
sters protected them from weight loss post challenge, while FILORAB1 vaccinated animals
showed weight loss. The absence of infectious virus in the lungs and nasal turbinates of the
CORAVAX vaccinated animals at day 3 p.c. suggests that CORAVAX can control viral
transmission.
In humans, SARS-CoV-2 infection presents histopathologically as an acute viral interstitial
pneumonia, typically of a lobar nature. Features include consolidation of air spaces, alveolar
septal thickening, lymphocytic infiltration of airspaces and airways, pleuritis, pleural effusion,
and perivascular cuffing [47]. Acute lung injury typically accompanies this pneumonia in the
form of diffuse alveolar damage (DAD), the histopathological correlate of acute respiratory
distress syndrome [48]. Presentation in the Syrian golden hamster model is broadly similar to
what is observed in severe human disease [49]. In this study, we found that overall pathology
scores and two component scores were improved in CORAVAX vaccinated animals following
SARS-CoV-2 challenge. We observed an improvement in elements of pathology related to
acute immune cell activity such as airway infiltration by immune cells, and the overall number
and size of inflammatory foci (defined in part by immune cell infiltration) in the absence of
statistically significant improvement in elements of pathology more closely tied to damage
resulting from the immune response to infection (septal thickening in particular). This pattern
is very similar to what we observe when animals are permitted to clear the infection naturally.
This result is therefore within the realm of what might be expected from a vaccine that pro-
vides protection without sterilizing immunity, as it suggests that although viral replication
likely did occur after challenge, the virus was rapidly cleared, and the tissue repair process was
underway when the animals were euthanized. Collectively these results suggest that CORA-
VAX can dramatically reduce disease in vaccinated animals.
Regarding the adjuvant, we previously showed that GLA-SE adjuvanted FILORAB1 rabies
virus-based EBOLA vaccine, protected 100% of NHPs challenged with Ebola, an improvement
from the unadjuvanted FILORAB1 vaccine, which was less protective. This protection was
attributed to the strong Th1 biased immune response induced by GLA-SE, which is a synthetic
TRL4 agonist [20]. To induce a stronger Th1 biased response in our study, we utilized another
TRL4 agonist, MPLA-AddaVax, because MPLA is a TLR4 agonist and AddaVax is squalene-
based oil-in-water nano-emulsion (similar to SE component in GLA-SE). MPLA has been
shown to enhance the immunogenicity and protection of the rabies vaccine with induction of
plasma cell responses. MPLA vaccinated mice accelerated the activation of dendritic cells,
improving T-dependent B cell responses driving antibody production that skewed towards a
strong Th1 bias [4750]. As seen for mild COVID-19 patients, a Th1 biased immune response
is beneficial for protection protection against disease [48–51]. Our previous work demon-
strated that CORAVAX induced a strong Th1 biased immune response in Balb/C mice by gen-
erating higher IgG2a antibodies [30]. In Syrian hamsters, CORAVAX vaccinated animals
induced a stronger S1 IgG2/3 response before challenge. More importantly, the CORAVAX
vaccinated hamsters mounted a significantly higher S1 IgG2/3 on day 15 p.c. than the
FILORAB1 vaccinated animals. We could not detect S1 IgG1 responses, but we could detect
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RABV-G IgG1 responses, suggesting that S1 IgG1 antibodies are present at low levels or
absent.
In conclusion, our RABV-vectored COVID-19 vaccine CORAVAX is efficacious and is
able to prevent viral replication and reduce disease in Syrian hamsters. CORAVAX also serves
as a vaccine against RABV because it induces high RABV VNA. Future studies assessing the
efficacy of a single CORAVAX vaccine will be performed since we did not see a dramatic
booster effect in immune responses among the hamsters. CORAVAX production should be
relatively easy as it would follow the existing RABV vaccine manufacturing facilities and tech-
nologies. Additionally, the use of the adjuvant might allow for dose sparing. These results war-




The studies were carried out in a strict accordance with the recommendations described in the
Guide for the Care and Use of Laboratory Animals of the National Research Council. UTMB
is an AAALAC-accredited institution, and all animal work was approved by the IACUC Com-
mittee of UTMB. All efforts were made to minimize animal suffering and all procedures
involving potential pain were performed with the appropriate anesthetic or analgesic. The
number of hamsters used was scientifically justified based on statistical analyses of virological
and immunological outcomes. Seven-week-old golden Syrian female hamsters (Envigo) were
anesthetized with 5% isoflurane prior to immunization and blood collections and with keta-
mine/xylazine prior to the SARS-CoV-2 challenge. Animals were monitored daily for weight
loss and signs of disease. Half of the animals in each group (6 vaccinated and 6 control ham-
sters) was euthanized by overdose of injectable anesthetics on day 3 p.c. (day 63) for viral load
determination.
Antibodies
The following SARS-CoV-2 specific human monoclonal antibodies were kindly provided by
Distributed Bio: COVID-19 DB_A03-09, 12; DB_B01-04, B07-10, 12; DB_C01-05, 07, 09, 10;
DB_D01, 02; DB_E01-04, 06, 07; DB_F02-03.
Viruses
The SARS-CoV-2 strain used in this study is the first U.S. isolate SARS-CoV-2 USA_WA1/
2020 from the Washington State patient identified on January 22, 2020 [31]. Passage 3 was
obtained from the World Reference Center for Emerging Viruses and Arboviruses
(WRCEVA) at UTMB. Virus stocks were propagated in Vero E6 cells. The challenge stock
used in this study is passage 5. The recombinant SARS-CoV-2 expressing Neon Green protein
(SARS-CoV-2-mNG) [49] used in the neutralization assay was developed by Dr. Pei-Yong Shi
at UTMB. Virus stocks were propagated in Vero E6 cells and a passage 4 was used.
Vaccine production and purification
Recombinant RABV were recovered, purified, inactivated, and titered. Briefly, X-tremeGENE
9 transfection reagent (Millipore Sigma, Cat# 6365809001) was used to cotransfect the full-
length viral cDNA clone encoding CORAVAX along with the plasmids encoding RABV N, P,
and L proteins and the T7 RNA polymerase into BEAS-2B human lung cells in 6-well plates
(RABV). At 8 days post transfection, supernatant was collected, filtered through a 0.22 μm
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membrane filter (Millipore), and titrated on VERO cells. The presence of recombinant virus
was verified by immunostaining with monoclonal antibody against the nucleoprotein (FujiRe-
bio, Cat# 800–092) and polyclonal antiserum against the S1 domain (Thermo Fisher, Cat#
PA581798). The filtered virus was then used to inoculate VERO cells seeded in Cellstack Cul-
ture Chambers (Corning) and propagated in VP-SFM medium (Thermo Fisher Scientific)
over a period of 18 days. Supernatant collected on day 10 post infection was filtered through
0.45 μm PES membrane filters (Nalgene) and layered onto 20% sucrose in DPBS. Virions were
sedimented by ultracentrifugation in a SW32 rotor for 1.5 h at 25,000 rpm. Viral particles were
resuspended in phosphate-buffered saline (PBS) and inactivated with 50 μl per mg of particles
of a 1:100 dilution of β-propiolactone (BPL, Millipore Sigma, Cat# P5648) in cold water. The
absence of infectious particles was verified by inoculating BSR cells with 10 μg of BPL-inacti-
vated viruses over 3 passages.
Animal studies
The studies were carried out in a strict accordance with the recommendations described in the
Guide for the Care and Use of Laboratory Animals of the National Research Council. UTMB
is an AAALAC-accredited institution and all animal work was approved by the IACUC Com-
mittee of UTMB. All efforts were made to minimize animal suffering and all procedures
involving potential pain were performed with the appropriate anesthetic or analgesic. The
number of hamsters used was scientifically justified based on statistical analyses of virological
and immunological outcomes.
Vaccination and SARS-CoV-2 challenge
Seven-week-old golden Syrian female hamsters (Envigo) were anesthetized with 5% isoflurane
prior to immunization and blood collections and with ketamine/xylazine prior to the SARS-CoV-
2 challenge. On day 0, 12 animals per group were inoculated with 10 μg of CORAVAX or
FILORAB1 (control vaccine), adjuvanted with MPLA-AddaVax (Per animal: 5 μg MPLAs, Invi-
voGen, cat# vac-mpls; 50μL AddaVax, InvivoGen, cat#-adx-vac) in a 100 μl injection volume via
the intramuscular route (50 μl per hind leg). The animals received a boost on day 28. Vena cava
blood collections were performed two days prior the immunization, on day 26 and day 56. On
day 60, vaccinated and control animals were exposed intranasally to the targeted dose of 105 PFU
of isolate SARS-CoV-2. Animals were monitored daily for weight loss and signs of disease. Half of
the animals in each group (6 vaccinated and 6 control hamsters) was euthanized by overdose of
injectable anesthetics on day 3 p.c. (day 63) for viral load determination. The remaining animals
(5 vaccinated and 6 control hamsters) were euthanized on day 15 post challenge (p.c.) (day 75).
One animal in the CORAVAX group did not recover from anesthesia after challenge.
Recombinant proteins for ELISA
Purification of the HA-tagged protein from the supernatant of transfected cells for
ELISA. Sub-confluent T175 flasks of 293T cells (human embryonic kidney cell line) were
transfected with a pDisplay vector encoding amino acids 16 to 682 of SARS-CoV-2 S (S1)
fused to a C-terminal hemagglutinin (HA) peptide using X-tremeGENE 9 reagent (Millipore
Sigma, Cat# 6365809001). Supernatant was collected 6 days post-transfection, filtered through
0.22 um PES membrane filters (Nalgene) and the loaded onto an anti-HA agarose (Pierce,
Cat# 26182) column equilibrated in PBS. After washing with ten bed volumes of PBS the col-
umn was loaded with 2 column volumes of HA peptide at a concentration of 400 μg/ml in PBS
and incubated overnight at 4 ˚C. The following day, the protein was eluted with 2 column vol-
umes of HA peptide followed by two column volumes of PBS. Fractions were collected and
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analyzed by western blotting with polyclonal antiserum against the S1 domain (Thermo Fisher,
Cat# PA581798). Peak fractions were then pooled and dialyzed against PBS in 10,000 molecu-
lar weight cutoff (MWCO) dialysis cassettes (Thermo Fisher Scientific) to remove excess HA
peptide. After dialysis, the protein was quantitated by UV spectrophotometry and frozen in
small aliquots at −80 ˚C.
Purification of the RBD-His protein for ELISA
RBD-HIS [52]: The SARS CoV-2 RBD-His tagged plasmid was purchased from Bei Resources
(NR-52309). Sub-confluent T175 flasks of 293T cells (human embryonic kidney cell line) were
transfected with the RBD-His tagged plasmid using X-tremeGENE 9 reagent (Millipore Sigma,
Cat# 6365809001). Supernatant was collected 6 days post-transfection and filtered through 0.22
μm PES membrane filters (Nalgene). The 5 mL HisTALON cartridge (Clontech Laboratories, Cat
# 635683) column was equilibrated with 10 column volumes of Equilibration Buffer (HisTALON
Buffer Set, Clontech Laboratories, Cat# 635651). The filtered supernatant was loaded onto the
HisTALON cartridge (Clontech Laboratories, Cat# 635683) column at a speed of 1 mL/min. After
washing with ten column volumes of Wash Buffer (prepared by mixing 6.6 parts of Elution Buffer
with 93.4 parts of Equilibration Buffer of the HisTALON Buffer Set), the sample is eluted (at a
flow rate of ~1 ml/min) with approximately 8 column volumes of Elution Buffer, collecting 1 ml
fractions. The sample protein concentration was assessed by measuring the absorbance of the
eluted fractions at 280 nm (Nanodrop, Thermo Fisher Scientific). Eluted fractions were analyzed
by western blotting with a mouse monoclonal RBD specific antibody (InvivoGen, Cat# srbd-
mab10). Peak fractions were then pooled and dialyzed against PBS in 10,000 molecular weight
cutoff (MWCO) dialysis cassettes (Thermo Fisher Scientific). After dialysis, the protein was quan-
titated by UV spectrophotometry and frozen in small aliquots at −80 ˚C.
Enzyme-linked immunosorbent assay
To determine antibody responses to the S protein of SARS-CoV-2, an indirect ELISA was
developed utilizing purified S1 or receptor binding domain (RBD) protein. The production of
the recombinant proteins is described above. Humoral responses to SARS-CoV-2 S1 and RBD
protein were measured by an indirect ELISA. We tested individual hamster sera by enzyme-
linked immunosorbent assay (ELISA) for the presence of IgG specific to SARS-Cov-2 S1 or
RBD. In order to test for anti-SARS CoV-2 S1 humoral responses, we produced soluble S1 or
RBD as described above. The two recombinant proteins were resuspended in coating buffer
(50 mM Na2CO3 [pH 9.6]) at a concentration of 0.5 μg/mL of S1 or 2 μg/mL of RBD, and then
they were plated in 96-well ELISA MaxiSorp plates (Nunc) at 100 μl in each well. After over-
night incubation at 4 ˚C, plates were washed 3 times with 1× PBST (0.05% Tween 20 in 1×
PBS), followed by the addition of 250 μl blocking buffer (5% dry milk powder in 1× PBST) and
incubation at room temperature for 1.5 h. The plates were then washed 3 times with PBST and
incubated overnight at 4 ˚C with serial dilutions of sera (in triplicate) in 1× PBST containing
0.5% BSA. Plates were washed 3 times the next day, followed by the addition of HRP-conju-
gated goat anti-Syrian hamster IgG secondary antibody (Jackson immunoresearch, Cat# 107-
035-142, 1:8000 in PBST) or mouse anti-hamster-IgG2/3-HRP (Southern Biotech, Cat# 1935–
05, 1:8000 in PBST) or mouse anti-hamster-IgG1-HRP (Southern Biotech, Cat# 1940–05,
1:8000 in PBST) for 2 h at RT. After the incubation, plates were washed three times with PBST,
and 200 μl of o-phenylenediamine dihydrochloride (OPD) substrate (Sigma) was added to
each well. The reaction was stopped by the addition of 50 μl of 3 M H2SO4 per well. Optical
density was determined at 490 nm (OD490) and 630 nm (OD630) using an ELX800 plate
reader (Biotek Instruments, Inc., Winooski, VT). Plates were incubated for 15 min (IgG) or 20
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min (IgG2/3 or IgG1) with OPD substrate before the reaction was stopped with 3 M H2SO4.
Data were analyzed with GraphPad Prism (Version 8.0 g) using 4-parameter nonlinear regres-
sion to determine the titer at which the curves reach 50% of the top plateau value (50% effec-
tive concentration [EC50]).
Neutralizing antibody response
Sera collected from animals were tested for neutralizing capabilities against SARS-CoV-2.
Briefly, serum samples were heat-inactivated (30 min at 56˚C), and then 10-fold diluted sera
were further diluted in a 2-fold serial fashion, and 60 μl of each serum dilution was mixed with
60 μl of SARS-CoV-2-mNG (200 PFU) [49–53]. The serum/virus mixtures were incubated for
1 h at 37˚C. 100 μl of the serum/virus mixtures were then transferred to Vero E6 cell monolay-
ers in flat-bottom 96-well plates and incubated for 2 days at 37˚C. Virus fluorescence was mea-
sured with a Cytation Hybrid Multi-Mode reader at 488 nm (Biotek Instruments).
Tissue processing and viral load determination
Animals were euthanized on days 3 and 15 p.c., and lungs and nasal turbinates were harvested.
Right lungs and nasal turbinates were placed in L15 medium supplemented with 10% fetal
bovine serum (Gibco) and Antibiotic-Antimycotic solution (Gibco). Tissues were homoge-
nized using the TissueLyser II system (Qiagen) and tissue homogenates were aliquoted and
stored at -80˚C. Tissue homogenates were titrated on Vero E6 cell monolayers in 24-well plates
to determine viral loads. Plates were incubated 3 days at 37˚C before being fixed with 10% for-
malin and removed from containment. Plaques were visualized by immunostaining with 1 μg/
mL cocktail of 37 SARS-CoV-2 specific human antibodies kindly provided by Distributed Bio.
As the secondary antibody, HRP-labeled goat anti-human IgG (SeraCare) was used at dilution
1:500. Primary and secondary antibodies were diluted in 1X DPBS with 5% milk. Plaques were
revealed by AEC substrate (enQuire Bioreagents).
Viral RNA copies by qRT-PCR
Tissue homogenates were mixed with TRIzol Reagent (Life Technologies) at a 1:5 volume ratio
of homogenate to TRIzol. The RNA extraction protocol for biological fluids using TRIzol
Reagent was followed until the phase separation step. The remaining RNA extraction was
done using the PureLink RNA Mini Kit (Ambion). The quantity and quality (260/280 ratios)
of RNA extracted was measured using NanoDrop (Thermo Fisher). SARS-CoV-2 nucleopro-
tein cDNA was generated from RNA from Bei Resources (NR-52285) by One-Step RT PCR
(SuperScript IV, Thermo Fisher) with primers SARS CoV-2 N IVT F1 (5’-GAATTCTAAT
ACGACTCACTATAGGGGATGTCTGATAATGGACCC-3’) and SARS CoV-2 N IVT R1
(5’- GCTAGCTTAGGCCTGAGTTGAGTCAGCACTGCT-3’). The SARS-CoV-2 N standards
were generated by in-vitro transcription of the generated SARS-CoV-2 N cDNA using the
MegaScript T7 Transcription kit (Invitrogen), followed by using the MEGAclear Transcription
Clean-Up Kit. Aliquots of 2 ×1010 copies/μL were frozen at -80˚C. Five microliters of RNA per
sample were run in triplicate, using the primers 2019-nCoV_N2-F (5’- TTACAAACATTG
GCCGCAAA-3’), 2019-nCoV_N2-R (5’-GCGCGACATTCCGAAGAA-3’) and probe 2019-
nCoV_N2-P-FAM (5’-ACAATTTGCCCCCAGCGCTTCAG-3’).
Histopathology
Following euthanasia, necropsy was performed, gross lesions were noted, and left lungs were
placed in 10% formalin for histopathological assessment. After a 24-h incubation at 4˚C, lungs
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were transferred to fresh 10% formalin for an additional 48-hour incubation before removal
from containment. Tissues were processed by standard histological procedures by the UTMB
Anatomic Pathology Core, and 4 μm-thick sections were cut and stained with hematoxylin
and eosin. Sections of lungs were examined for the extent of inflammation, type of inflamma-
tory foci, and changes in alveoli/alveolar septa/airways/blood vessels in parallel with sections
from uninfected or unvaccinated lungs. The blinded tissue sections were semi-quantitatively
scored for pathological lesions using the criteria described in S1 Table. Examination was per-
formed with an Olympus CX43 microscope at magnification 40X for general observation and
100X magnification for detailed observation. Each section was scored by a trained member of
staff.
Statistical analysis
Statistical analyses were performed with GraphPad Prism for Windows (version 6.07). P<0.05
was considered significant. P> 0.123 (ns), P < 0.033 (�), P< 0.002 (��), P< 0.001 (���).
Biocontainment work
Work with SARS-CoV-2 was performed in the BSL-4 facilities of the Galveston National Labo-
ratory according to approved standard operating protocols.
Supporting information
S1 Table. Histopathology scoring criteria.
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